Report Highlights
The global infectious diseases market reached $238.5 billion in 2022 and should reach $300.8 billion by 2027, with a compound annual growth rate (CAGR) of 4.7% during the forecast period of 2022-2027.
Report Includes
- 22 data tables and 36 additional tables
- A brief general outlook and in-depth analysis of the current and future global markets for pandemics (infectious diseases) control
- Analyses of the global market trends, with market revenue (sales figures) for 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Discussion of industry growth driving factors and major technology issues and challenges affecting the market for pandemics control as a basis for projecting demand in the next few years (2023-2028)
- Estimation of the actual market size and revenue forecast for global market for pandemic control in USD million values, and corresponding market share analysis based on the disease type, therapeutics, vaccines, diagnosis, end user, and region
- Assessment of the market growth opportunities, SWOT analysis of the leading companies engaged in development of infectious disease products and viral vaccines, regulatory environment, pipeline analysis, recent approvals, emerging trends and technologies, and the COVID-19 impact on the marketplace
- Review of the key patent grants and patent applications on the market for pandemic control
- Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities, market development strategies, and company revenue share analysis
- Identification of major stakeholders and analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
- Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche, Johnson & Johnson, Merck & Co., and Pfizer
Report Scope
The scope of this study encompasses an investigation of the current pandemics. BCC Research analyzes each disease type, determines its current market status based on the available or approved diagnostic methods for the disease, type of intervention approved (therapeutic or vaccine) and estimates the current market for each pandemic disease. It also examines the future market for the diseases and presents forecasts of growth over the next six years.
The current report provides detailed analysis of the market's drivers, challenges and opportunities. The report also covers market projections to 2027 and market share for key market players. The report includes the company profiles of the key players with detailed information about business segments, financials, product portfolios and recent developments. The report also provides the impact of the COVID-19 pandemic on this market.
Report Synopsis
Report Metrics | Details | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2021 | ||||||||||||||||||||||||||||
Forecast period considered | 2022-2027 | ||||||||||||||||||||||||||||
Base year market size | $248.9 billion | ||||||||||||||||||||||||||||
Market size forecast | $300.8 billion | ||||||||||||||||||||||||||||
Growth rate | CAGR of 4.7% for the forecast period of 2022-2027 | ||||||||||||||||||||||||||||
Units considered | $ Millions | ||||||||||||||||||||||||||||
Segments covered | Disease Type, Region, Technology Type | ||||||||||||||||||||||||||||
Regions covered | North America, Europe, Asia-Pacific, Rest of the World (RoW) | ||||||||||||||||||||||||||||
Key Market Drivers |
|
||||||||||||||||||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.
Report Highlights
The total market for pandemic infectious disease products broken down by disease type was $31.6 billion in 2011 and $35.6 billion in 2012. The market is expected to rise at a CAGR of 9.3% and reach nearly $55.6 billion by 2017.
The report provides:
- An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS
- Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Clarification of the HIV/AIDS pandemic and ongoing efforts to control it
- Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases
- Trends based on projected sales through 2017 for new products, including supporting analyses for projections.
- Comprehensive company profiles of major players.
Report Highlights
-
The market for "new antibiotics" and HIV/AIDS treatments was $6.2 billion in 2003 and is rising at an AAGR (average annual growth rate) of 9.1%. It is expected to reach $10.1 billion in 2008.
-
New antibiotics (products introduced in 2000 or later) will move from a market share of just under 4% in 2003 to a projected market share of more than 20% in 2008, rising at an AAGR of nearly 34%.
-
Drugs to treat HIV/AIDS will not see as dramatic an annual growth rate, but will continue to expand at a healthy pace as a result of recently introduced products.
-
In this category, combination products are taking market share away from single-chemical agents, and this trend will continue throughout the forecast period.
Related Reports
Global Markets for Vaccine Technologies
The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.
Influenza Vaccines: Global Markets
The global influenza vaccines market is estimated to increase from $6.9 billion in 2021 to $10.1 billion by 2026, at a compound annual growth rate (CAGR) of 7.9% during the forecast period of 2021-2026.
Global Markets for Infectious Disease Treatments
The global market for infectious disease treatments should grow from $72.4 billion in 2021 to $106.3 billion by 2026, at compound annual growth rate (CAGR) of 8.0% for the period of 2021-2026.
COVID-19 Diagnostics and Kits: Global Markets
The global COVID-19 diagnostics market should reach $12.0 billion by 2025 from $10.8 billion in 2020 at a compound annual growth rate (CAGR) of 2.2% for the forecast period of 2020 to 2025.
Recent Reports
Rare Disease Diagnostics: Technologies and Global Markets
The global market for rare disease diagnostics is estimated to increase from $21.6 billion in 2024 to reach $34.7 billion by 2029, at a compound annual growth rate (CAGR) of 9.9% from 2024 through 2029.
Breakthrough Therapies: Market Dynamics and Investment Opportunities
The global market for breakthrough therapy drugs was valued at $133.3 billion in 2023. This market is expected to grow from $150.6 billion in 2024 to $287.5 billion by 2029, at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2029.
Softgel Capsules: Global Markets
The global market for softgel capsules was valued at $7.4 billion in 2023. The market is expected to grow from $7.9 billion in 2024 to $11.5 billion by 2029, at a compound annual growth rate, or CAGR, of 7.7% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Active Pharmaceutical Ingredients: Global Markets
The global market for active pharmaceutical ingredients (APIs) is estimated to increase from $247.8 billion in 2023 to reach $347.9 billion by 2029, at a compound annual growth rate (CAGR) of 5.9% from 2024 through 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More